France-based Exeliom Biosciences is developing EXL01, a first-in-class drug candidate that uses gut bacteria sourced from the microbiome to produce impactful immunotherapies across indications.
Exeliom’s Bacteria-Focused Approach To Immunotherapy
In Vivo sat down with Benjamin Hadida, CEO of Exeliom, at the 2024 BIO International Convention to discuss how the company is using its first-in-class drug candidate to improve therapeutic responsiveness in immuno-oncology, immuno-inflammation and rare disease.
